News About: Pharm. Industry
Janssen Korea new CEO
Janssen Korea says it has named Kim Sang-jin, CEO of Janssen Taiwan, to replace Choi Tai-hong. Kim will serve as CEO of Janssen Korea on Jan. 1, 2009.
Company officials said Kim was credited with his leadership in ...
Foreign generics will hurt local pharmaceutical sector
There are growing concerns over the movement of foreign generic makers, such as Rabaxy and Teva, to make inroads into the Korean market if a U.S.-Korea free trade agreement goes through.
This worst-case scenario, i...
Korean drugmakers urged to focus on profitable products
Overall, Korean pharmaceutical firms are hesitating to make voluntary withdrawal of many unprofitable products due to internal conflicts between development and marketing departments.
“It is necessary to implement ...
Neu2000, promising neuroprotectant to treat ischemic stroke
Neu2000 remains the primary focus of the drug’s development. Neu2000’s strong anti-oxidation activity, its potent NMDA antagonist activity, and its anti-zinc protective activity make it a promising neuroprotectant to ...
Concerns mounting over direct transaction
Wholesalers are nervous about the recent direct dealings between clinics and pharmaceutical firms, according to pharmaceutical business sources.
The sources said that some pharmaceutical firms have directly provide...
Green Cross signs $6.6 million vaccine deal
Green Cross Corp., Korean drugmaker, said Wednesday it has signed a deal with the Pan American Health Organization, a regional body of the World Health Organization, to provide $6.6 million worth of chickenpox vaccine...
SK Chemicals to lead in life science business
SK Chemicals says that Thailand based Indorama Ventures Public Company Limited has acquired all of SK stakes in PT SK Keris in Indonesia and SK Eurochem in Poland.
“Through this sell-out plan, SK Chemicals will ste...
Daewoong’s Ursa picked as one of 2010 global leading brands
Daewoong Pharmaceutical’s Ursa (ursodeoxycholic acid), which has gained favorable reputation as its immensely popular liver medicine since its launching in 1961, were selected as Korea’s global top brand, the company ...
Government urged to clarify consulting/lecturing fees
Pharmaceutical companies are hesitating to hold non-commercial consulting and/or lecturing sessions under the new rebate ban guidelines.
However, due to the unclear relevant regulation, companies have called on the...
Guideline for anti-rebate provisions clarified
Providing a doctor with a meal worth more than 100,000 won during a product detailing meeting will be considered a rebate activity in the pharmaceutical industry, according to the Ministry of Health and Welfare.
In...
